Personalisiertes Risikomanagement für das maligne Melanom

[1]  V. Gotlieb,et al.  The rapidly evolving therapies for advanced melanoma--Towards immunotherapy, molecular targeted therapy, and beyond. , 2016, Critical reviews in oncology/hematology.

[2]  S. Rosso,et al.  Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma. , 2015, JAMA oncology.

[3]  P. Baade,et al.  More people die from thin melanomas (⩽1 mm) than from thick melanomas (>4 mm) in Queensland, Australia. , 2015, The Journal of investigative dermatology.

[4]  Robert W Cook,et al.  Development of a Prognostic Genetic Signature to Predict the Metastatic Risk Associated with Cutaneous Melanoma , 2015, Clinical Cancer Research.

[5]  A. Heinecke,et al.  Abstract 2861: Independent validation of a prognostic gene-signature based risk score in formalin-fixed paraffin-embedded melanomas , 2014 .

[6]  R. Elashoff,et al.  Final trial report of sentinel-node biopsy versus nodal observation in melanoma. , 2014, The New England journal of medicine.

[7]  Dirk Schadendorf,et al.  Melanoma in 2013: Melanoma—the run of success continues , 2014, Nature Reviews Clinical Oncology.

[8]  Andreas von Deimling,et al.  Survival According to BRAF-V600 Tumor Mutations – An Analysis of 437 Patients with Primary Melanoma , 2014, PloS one.

[9]  C. Berking,et al.  A nine-gene signature predicting clinical outcome in cutaneous melanoma , 2013, Journal of Cancer Research and Clinical Oncology.

[10]  C. Robert,et al.  New drugs in melanoma: it's a whole new world. , 2011, European journal of cancer.

[11]  I. V. D. van der Ploeg,et al.  Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  A. Lippold,et al.  Increased expression of the tumor suppressor PLZF is a continuous predictor of long-term survival in malignant melanoma patients. , 2008, Cancer biotherapy & radiopharmaceuticals.